Bibliographic Details
| Title: |
The burden of depressive disorders in musculoskeletal diseases: is there an association between mood and inflammation? |
| Authors: |
Chimenti, Maria Sole1, Fonti, Giulia Lavinia1, Conigliaro, Paola1, Triggianese, Paola1, Bianciardi, Emanuela2 emanuelabianciardi@libero.it, Coviello, Marialuce2, Lombardozzi, Ginevra2, Tarantino, Giulia2, Niolu, Cinzia2, Siracusano, Alberto2, Perricone, Roberto1 |
| Source: |
Annals of General Psychiatry. 1/4/2021, Vol. 20 Issue 1, p1-13. 13p. |
| Subject Terms: |
*ARTHRITIS prevention, *AFFECT (Psychology), *ARTHRITIS, *BLOOD-brain barrier, *MENTAL depression, *INFLAMMATION, *INTERLEUKINS, *MUSCULOSKELETAL system diseases, *HEALTH outcome assessment, *PSORIATIC arthritis, *RHEUMATOID arthritis, *PSYCHOLOGY of the sick, *SMOKING, *SPONDYLOARTHROPATHIES, *PSYCHOLOGICAL stress, *TUMOR necrosis factors, *OXIDATIVE stress, *LIFESTYLES |
| Abstract: |
Importance: Evidence emerged concerning how inflammatory arthritis and mood disorders can often occur in the same patient and show a similar clinical pattern. An overview of the rheumatological and psychiatric aspects of these diseases can certainly be useful for the improvement of patients' clinical and therapeutic management. Objective: The aim of this narrative review was to summarize existing literature about common pathogenetic and clinical aspects as a means of improving management and therapeutic approach in patients affected by rheumatoid arthritis, psoriatic arthritis and spondyloarthritis. Outcomes such as disease activity indexes and patient reported outcomes (PROs) were considered. Findings: Common pathogenetic pathways emerged between inflammatory arthritis and mood disorders. Pro-inflammatory mechanisms, such as TNFα, IL-6, IL-17 and oxidative stress factors as well as neurotransmitter alterations at the level of CNS and blood–brain barrier (BBB) cells are involved. The activation of these common pathogenetic pathways is, also, affected by the same triggers, such as smoking, stress, lifestyle, and evidence has emerged concerning the possibility of the clinical efficacy of using the same therapeutic approaches. Conclusions: The main causes of the variability in clinical studies outcomes are the rheumatological diseases considered, the prevalence of depression in the general population and in patients with rheumatological diseases and the type of depressive symptom examined. Patients affected by inflammatory arthritis can present symptoms and signs in common with mood disorders, leading to possible clinical overlap. There are still few studies analyzing this concept: they are extremely heterogeneous, both in the characteristics of the population taken into consideration and in the methods used for the definition of depressive disorder, but the suggestions of the data obtained so far are promising and deserve to be pursued. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of General Psychiatry is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
